Topical haemostatic agents in liver surgery: do we need them?  by Boonstra, Elizabeth A. et al.
REVIEW ARTICLE
Topical haemostatic agents in liver surgery: do we need them?hpb_065 306..310
Elizabeth A. Boonstra, I. Quintus Molenaar, Robert J. Porte & Marieke T. de Boer
Department of Surgery, Division Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, University of Groningen, Groningen,
the Netherlands
Abstract
Background: Worldwide, partial liver resections are increasingly being performed for primary or sec-
ondary hepatic malignancies. There are various techniques to reduce blood loss druing liver surgery.
Several topical haemostatic agents have been developed to improve haemostasis of the resection surface
and these agents are used more and more, even although the true effects remain unclear.
Methods: The present literature about the use of topical haemostatic agents in liver surgerywas reviewed.
Furthermore we conducted a Dutch national survey to explore the use of and belief in these agents in liver
surgery.
Results: The Dutch national survey among surgeons showed that topical haemostatic agents are
frequently used not only to lower intra-operative blood loss or shorten time to haemostasis, but even
more importantly, to reduce resection surface related complications such as bile leakage, postoperative
haemorrhage and abscess formation. Although various topical haemostatic agents have been shown to
reduce intra-operative time to haemostasis at the resection surface after liver resections, there is no
scientific proof that these topical haemostatic agents really reduce resection surface related complications.
Conclusion: This review highlights the need for more randomized clinical trials to investigate the efficacy
of topical haemostatic agents in reducing resection surface related complications.
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Introduction
Worldwide, partial liver resections are being performed for
primary or secondary hepatic malignancies with increasing fre-
quency. Although recent reports have shown improvement in
operative morbidity and mortality associated with hepatic
resection there is no uniformity between centres in the surgical,
anaesthetic and haemostatic techniques used. Specific factors con-
tributing to the improvement in operative risks have not been
clearly defined. Several studies have shown intra-operative blood
loss and transfusion requirements to be risk factors for post-
operative morbidity and mortality.1–4 According to these results, a
main focus in hepatic resections should be reduction of blood loss
and transfusion requirements.
During liver surgery, there are several techniques to reduceblood
loss.Reductionof the central venouspressureduring transectionof
the liver parenchyma has been shown to significantly reduce blood
loss.5,6 Vascular occlusion techniques, such as inflow occlusion and
total vascular occlusion,have also been shown to potentially reduce
blood loss during hepatic resection.7 The device used for tran-
section of the liver parenchyma might also influence blood loss,8
even although none of these devices or techniques have gained
unanimous acceptance among liver surgeons.
Besides techniques applied during resection, several topical
agents have been developed to improve haemostasis of the resec-
tion surface.Apart from their haemostatic potential, these haemo-
static agents are also used with the aim to prevent bile leakage,
which is still a clinically important complication after liver
surgery. Bile leakage from the resection surface has been reported
in up to 15% of the patients after partial liver resections. Only a
few clinical trials on the use of haemostatic agents have focused on
resection surface-related complications after liver resection. Hae-
mostatic agents are used more and more, even although the true
effects remain unclear.
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This review will focus on the use of topical haemostatic agents
in liver surgery. The rationale of different topical agents will be
discussed followed by the results of a Dutch national survey on
the use of topical haemostatic agents by liver surgeons in The
Netherlands.
Topical haemostatic agents
Topical haemostatic agents can be divided into two groups
(see Table 1). The first group consists of agents that only provide
a matrix for endogenous coagulation. Available matrices are
those that are made of collagen, cellulose or gelatine. These
agents do not contain active components. The second group
consists of agents that do contain active components, the fibrin
sealants. These agents mimic endogenous coagulation. A few
products available combine a matrix for coagulation with active
haemostatic components, the so-called ‘carrier-bound fibrin
sealants’.
The final step in the normal coagulation cascade, the formation
of fibrin from fibrinogen under the influence of thrombin, is
mimicked by fibrin sealants (see Fig. 1). These agents contain
separated, virus inactivated, human fibrinogen and thrombin. The
composition of the available sealants differs mainly in the concen-
tration of fibrin and thrombin and the addition of calcium or
antifibrinolytic components, such as aprotinin.When applied, for
example, to a resected liver surface, the two components mix and
reproduce the last step of the coagulation cascade. This leads to
the gradual polymerization of fibrinogen by hydrogen bonding
and electrostatic reactions into fibrin fibres. These fibres form a
three-dimensional structure with the appearance of a gel. Factor
XIII (fibrin-stabilizing factor), activated by thrombin in the
presence of calcium ions, converts the bonds between the fibrin
monomers into covalent bonds. This cross-linking leads to the
formation of a stable and insoluble fibrin clot.Most fibrin sealants
also contain an antifibrinolytic agents, usually aprotinin or tran-
examic acid. These agents inhibit the degradation of the fibrin clot
by proteolytic enzymes.9
Most fibrin sealants are packed in a dual syringe system.Hereby
thrombin and fibrinogen are separated. They mix at the end of the
syringes or in a connector just before contact with the resection
surface. Another method for applying fibrin sealant is as a spray.
The earlier mentioned carrier-bound fibrin sealants combine the
active agents in the fibrin sealant with a matrix for coagulation.
Instead of using ready-to-use carrier-bound fibrin sealants, it is
also possible to combine a fibrin sealant with amatrix of choice, in
this way creating a carrier-bound fibrin sealant. The ideal topical
agent should have the capacity to seal small vessels and bile ducts
of the resection surface, be safe and easy to use.
Little is known about the effect of bile on the active sub-
stances of topical haemostatic agents. In the past, experimental
research was performed to show the effect of bile on blood
clotting. These studies have shown that bile salts, especially
taurocholate or desoxycholate, are responsible for delaying
blood clotting by counteracting the activities of thrombin and
prothrombin.10,11
Use of haemostatic agents in liver surgery:
results of a Dutch survey
Topical haemostatic agents are increasingly used in liver surgery.
A Japanese survey found that 60% of surgeons performing
liver surgery routinely use haemostatic materials such as fibrin
sealants.12
In 2004, we conducted a web-based nation-wide survey to
explore the surgical attitudes and preferences regarding hepatic
resections among Dutch surgeons, focusing on haemostasis.
In our survey, the following parameters were assumed to be of
importance: anaesthetic techniques, vascular occlusion tech-
niques, haemostatic techniques and the use haemostatic agents.
One of our goals was to determine whether surgeons believe in
the effect of haemostatic agents in reducing resection surface-
Table 1 Different topical haemostatic agents used in surgery.
Examples of agents between brackets
Agents providing a
matrix for
coagulation
Collagen (Tissufleece®, Novacol® Lyostipt®,
Antema®, Avitene®, Duracol®)
Gelatine (Gelfoam®, Spongostan® Gelita®)
Cellulose (Nu-knit®, Surgicell®)
Agents that mimic
coagulation
Fibrin sealants (Tisseel® or Tissucol®,
Quixil® or Crosseal®, Vivostat®,
Beriplast®, Biocol® Bolheal®, Hemaseel®)
Carrier-bound fibrin sealants (FloSeal®
Tachosil®, Costasis®)
Figure 1 The final step in the normal coagulation cascade, the for-
mation of fibrin out of fibrinogen under the influence of thrombin, is
mimicked by fibrin sealants
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related complications. Questionnaires were sent by e-mail to all
practicing surgeons in the Netherlands. E-mail addresses were
obtained from the Dutch Surgery Association (‘Nederlandse
Vereniging voor Heelkunde’). The response rate was 69% (590/
859). Hepatic resections were performed by 96 out of the 590
respondingsurgeons, of whom 24 only performed wedge or
segmental resections. Seven surgeons sometimes performed
larger liver resections but never hemihepatectomies. Sixty-seven
(11%) surgeons in the Netherlands reported that they regularly
perform major partial liver resections (e.g. hemihepatectomies).
All of these surgeons were working in a teaching hospital (n =
31) or in a university medical centre (n = 36). Here we report
only on the surgical practice of those 67 surgeons performing
major liver resections.
The estimated number of liver resections in the Netherlands is
around 500 per year, but there are no valid data on complete
numbers. In our survey, 41 (69%) surgeons performed less than
10 resections per year, whereas 26 (31%) surgeons performed
more than 10 per year. Data on surgical methods used for transec-
tion of the hepatic parenchyma are presented in Fig. 2. The most
frequently used methods were CUSA (Cavitron Ultrasonic Sur-
gical Aspirator; Valley lab Inc., Boulder, CO, USA), argon beam
coagulation and the clamp crush technique.
Themajority of surgeons (58/67; 87%) used haemostatic agents
after resection of the liver parenchyma. More than half of them
used haemostatic agents routinely (57%), the rest of these sur-
geons used haemostatic agents only when indicated. The most
frequently used products were fibrin sealants (see Figs 3,4).
Forty-five per cent of the surgeons believed that fibrin sealants
reduce resection surface-related complications, 12% disagree and
43% were not sure about the effect of fibrin sealants on resection
surface-related complications (see Fig. 5).
From this nation-wide survey, we conclude that haemostatic
agents are frequently used in major liver surgery, not only for
haemostasis, but also with the aim to reduce resection surface-
related complications.
Evidence for the use of topical haemostatic
agents in liver surgery
In 2002, a systematic review was performed to examine the effi-
cacy of fibrin sealants in reducing intra-operative blood loss and
red cell transfusion in adult elective surgery. Types of surgery
involved in this study were prostatectomy, pulmonary, cardiac,
vascular, arthroplasty and liver surgery. Overall these results sug-
gested efficacy of fibrin sealants. For the trials that were conducted
in the setting of liver surgery, the use of fibrin sealants did not
show a significant reduction of intra- and post-operative blood
loss. A lack of blinding in the majority of the studies reviewed
raised concern about taking blood transfusion practice as a
response variable. The authors conclude that there were inad-
equate data provided to draw firm conclusions about the impact
of fibrin sealant use on clinically important endpoints.13
In liver surgery, haemostatic agents have shown to be effective in
improving time to haemostasis of the resection surface. Although
several products show a statistically significant reduction in time
What surgical devices for
transection of parenchyma do you
use?
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Figure 2 Results of a Dutch survey. Use of surgical devices among
67 surgeons who regularly perform major liver resections. Multiple
answers were possible
No
Occasional
Routine
14%
37%
49%
Do you use topical hemostatic
agents?
Figure 3 Results of a Dutch survey. Use of topical haemostatic
agents among 67 surgeons who regularly perform major liver
resections
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Figure 4 Results of a Dutch survey. Use of various types of topical
haemostatic agents among 58 out of 67 surgeons who use topical
haemostatic agents when performing liver resections. Multiple
answers were possible
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to haemostasis the question remains whether this is clinically
relevant. Also in liver surgery, intra-operative blood loss or blood
transfusionmight not be a relevant endpoint for the use of haemo-
static agents, because these agents aremainly used after transection
of the parenchyma, to seal the resection surface, while blood loss
is usually a problemduring transection andnot somuch thereafter.
Apart from intra-operative haemostasis, resection surface-
related complications, such as bile leakage and abscess formation,
are a major concern after liver resection. Patients suffering from a
biliary leakage after partial liver resection often require prolonged
hospitalization, additional interventions and have a worse prog-
nosis. The reported incidence of biliary leakage varies between
3.6% and 12%.14–16
In a prospective randomized trial, Frilling et al. compared a
carrier-bound fibrin sealant (Tachosil, Nycomed, Copenhagen,
Denmark) (n = 59) with argon beam coagulation (n = 62) as a
haemostatic agent in liver resection. Time to haemostasis was
significantly shorter in the group treated with the carrier bound
fibrin sealant (3.9 min vs. 6.3 min, P = 0.0007). Although the
incidence of bile leakage was slightly higher in the sealant group
(7% vs. 4%), the frequency of bile leakage and other adverse
events did not significantly differ between the groups.17
Another fibrin sealant, Crosseal (American Red Cross, Wash-
ington, DC, USA), (n = 58) was compared with other commer-
cially available haemostatic agents (n = 63) by Schwartz et al. Time
to haemostasis was shorter in the Crosseal group (282 vs. 468 min,
P = 0.006) and significantly more patients achieved haemostasis
within 10 min in this group (P = 0.003). There were significantly
less abdominal fluid collections and reoperations in the Crosseal
group compared with the control group, although this was a sec-
ondary endpoint.18
The largest prospective randomized controlled trial that com-
pared the combination of Tissucol (Baxter Immuno, Vienna,
Austria) and an absorbable collagen sponge (Johnson & Johnson)
(n = 150) with a control group (n = 150) showed no differences
between the two groups with regards to the need for blood trans-
fusion, post-operative complications (such as intra-abdominal
abscesses and other fluid collections or re-interventions).19
Another randomized controlled trial compared Costasis (Cohe-
sion Technologies Inc., Palo Alto, CA, USA) (n = 28) with a
collagen matrix (n = 29). Costasis is a composite of bovine
microfibrillar collagen and bovine thrombin that is mixed with
autologues plasma at the time of surgery.Although the sealant was
more effective in controlling bleeding than the collagen matrix,
there were no differences in transfusion need or adverse events.20
Theoretically, fibrin sealants might seal small bile ducts, which
is the rationale for surgeons to use fibrin sealants with the
assumption to reduce biliary complications after partial liver
resection. Only a few clinical trials have focused on the effect of
topical haemostatic agents on biliary leakage after liver resection.
Capusotti et al. performed a retrospective analysis in 610 patients
to identify the risk factors associated with bile leakage after liver
resection.Bile leakagewas defined as the drainage of 50 ml ormore
of bile from the surgical drain, or from drainage of an abdominal
collection, beyond the third post-operative day. After resection,
fibrin sealant was applied to the raw resection surface to improve
haemostasis.Atmultivariate analysis,use of fibrin sealant appeared
to be an independent protective factor against bile leakage.14
Ten years earlier, a French group had similar results. In a ran-
domized controlled trial, they compared the application of fibrin
sealant on a dry resection surface after hepatic resection (n = 38)
with a control group (n = 44). The fibrin sealant group had sig-
nificantly less drain production after 3 days. The concentration of
bilirubin in the drain fluid was also significantly lower in the fibrin
sealant group.21
In a retrospective study by Hayashibe et al., the combination of
fibrin sealant and a matrix, in this case a bioabsorbable polygli-
colic acid felt (n = 51), or fibrin sealant alone (n = 37) were
compared. Fibrin sealant alone was used from 2001 until 2003, the
combined agent was used from 2003 until 2005. The combination
of the two haemostatic agents was favourable for prevention of
bile leakage after hepatic resection. There was no bile leakage in
the group treated with the combined agent vs. three patients
(8.1%) with bile leakage in the fibrin-sealant group. Drawbacks of
this study were the low number of patients, the retrospective
design and the difference in treatment by time period.22
Directions for future research
Despite the clear effect of topical haemostatic agents on intra-
operative time to haemostasis, the efficacy of these agents regard-
ing clinically relevant post-operative outcome measures (such as
bile leakage or other resection surface-related complications)
remains to be demonstrated. More clinical trials are needed that
focus on resection surface-related complications instead of time
to haemostasis or transfusion requirements. Apart from the study
by Figueras et al., no previous trial was adequately powered to
show a significant difference in resection surface-related compli-
cations. As fibrin sealants have proven to be more effective in
Yes
No
Do not know
45%43%
12%
Do you believe that topical
haemostatic agents reduce resection
surface-related complication?
Figure 5 Results of a Dutch survey. Perception about the efficacy of
topical haemostatic agents among 67 surgeons who perform liver
resections
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haemostasis than matrix agents, further research should focus on
fibrin sealants or a combination of sealants with a matrix, the
so-called carrier-bound fibrin sealants. The concern of potential
viral transmission when fibrin sealants based on human plasma-
derived coagulation proteins are used, has lead to the development
of recombinant clotting factors. It is likely that these recombinant
products will replace products based on plasma-derived human
thrombin and fibrinogen in the future.
Conclusion
There is a large variety of topical haemostatic agents available for
use during surgery. The most frequently used agents are fibrin
sealants. Topical haemostatic agents are used on a large scale in
liver surgery.Despite a lack of clear evidence in the literature,most
surgeons believe that topical haemostatic agents reduce resection
surface-related complications after liver resection. Several studies
have been published about the use of haemostatic agents in liver
resection. Most of these studies lack clinically relevant primary
endpoints. When scrutinizing the literature, it is important to
distinguish the studies that have time to haemostasis as primary
outcome measure from those studies that focus on more clinically
relevant outcome measures, such as the need for post-operative
interventions to treat bleeding or resection surface-related com-
plications (e.g. biloma or other intra-abdominal fluid collections).
Fibrin sealants seem to be effective in reducing the time to hae-
mostasis, but their impact on reducing resection surface-related
complications remains contradictory. For this reason, larger, ran-
domized controlled trials are needed to show efficacy of haemo-
static agents in reducing those post-operative complications.
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